Geode Capital Management LLC Grows Position in Aileron Therapeutics, Inc. (NASDAQ:ALRN)

Geode Capital Management LLC grew its position in Aileron Therapeutics, Inc. (NASDAQ:ALRN) by 34.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 229,817 shares of the company’s stock after purchasing an additional 59,370 shares during the period. Geode Capital Management LLC owned approximately 1.06% of Aileron Therapeutics worth $814,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. KG&L Capital Management LLC acquired a new position in shares of Aileron Therapeutics in the 3rd quarter valued at about $46,000. Warberg Asset Management LLC purchased a new position in shares of Aileron Therapeutics in the 2nd quarter valued at $86,000. Sigma Planning Corp lifted its holdings in shares of Aileron Therapeutics by 68.3% during the 3rd quarter. Sigma Planning Corp now owns 212,410 shares of the company’s stock valued at $752,000 after acquiring an additional 86,185 shares in the last quarter. Nantahala Capital Management LLC boosted its position in Aileron Therapeutics by 82.1% during the 2nd quarter. Nantahala Capital Management LLC now owns 464,367 shares of the company’s stock worth $1,286,000 after purchasing an additional 209,367 shares during the period. Finally, University of Texas Texas AM Investment Management Co. purchased a new stake in Aileron Therapeutics during the 2nd quarter worth $4,925,000. 90.89% of the stock is owned by institutional investors and hedge funds.

Aileron Therapeutics Trading Up 9.3 %

Shares of NASDAQ ALRN opened at $2.11 on Friday. Aileron Therapeutics, Inc. has a 12-month low of $1.61 and a 12-month high of $7.42. The company has a market cap of $45.72 million, a P/E ratio of -0.68 and a beta of 2.24. The stock has a fifty day moving average price of $2.60 and a 200 day moving average price of $2.81.

Aileron Therapeutics Profile

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).